表紙
市場調査レポート

世界の非小細胞肺がん(NSCLC)治療市場とパイプライン分析

Global Non Small Cell Lung Cancer Market & Pipeline Insight

発行 KuicK Research 商品コード 322276
出版日 ページ情報 英文 750 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の非小細胞肺がん(NSCLC)治療市場とパイプライン分析 Global Non Small Cell Lung Cancer Market & Pipeline Insight
出版日: 2015年01月01日 ページ情報: 英文 750 Pages
概要

肺がんは、この数十年間で、世界中で最も多く見られる、がんの罹患率・死亡率の原因の1つになりました。肺は、1組の海綿状組織で、周囲の環境からガス交換を行う胸腔内にあります。これらの組織は、環境や細胞中に含まれる毒素によって容易に損傷し、長期間の暴露によって、がん性増殖(腫瘍)が示される可能性があります。肺がんは、大きく分けると2種類に分けられ、それぞれ小細胞肺がん(SCLC)と非小細胞肺がん(NSCLC)です。NSCLCは、喫煙習慣のある人によく見られる最も一般的な肺がんの種類です。

当レポートでは、世界の非小細胞肺がん(NSCLC)治療市場について調査分析し、市場の概要、治療の機序、市場力学(促進要因、課題、将来の見通し)、パイプライン(相別、企業別、国別)、臨床パイプライン、上市製品などについて、体系的な情報を提供しています。

第1章 非小細胞肺がんの概要

第2章 非小細胞肺がん治療法の機序

第3章 非小細胞肺がん治療市場の概要

  • 市場シナリオ
  • 非小細胞肺がんパイプラインの概要

第4章 非小細胞肺がん治療の市場力学

  • 市場促進要因
  • 課題

第5章 非小細胞肺がん治療市場の将来見通し

第6章 非小細胞肺がん治療薬パイプライン:相別、企業別、国別

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 認証前
  • 認証済み

第7章 上市された非小細胞肺がん治療薬

第8章 開発が中断/中止された非小細胞肺がん治療薬パイプライン

  • 開発報告なし
  • 中止
  • 中断

第9章 競合情勢

  • AstraZeneca
  • Biodesix
  • 中外製薬
  • Eli Lily
  • GlaxoSmithKline
  • Merck
  • Novartis AG
  • Pfizer
  • Roche
  • Transgene

図表

目次

Lung cancer has become one of the most prevalent cause of cancer related morbidity and mortality in past several decades across the world. Lungs are a pair of spongy tissues present in the thoracic cavity responsible for gaseous exchange from the surrounding environment. These tissues could be easily damaged by the toxins present in environment and cells may show cancerous growth upon longer exposure. The lung cancer is a collective term for cancer development in lungs, it could be divided into two broad categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). It has been observed that NSCLC is the most prevalent type of lung cancer commonly associated with the people practicing the bad habit of cigarette smoking.

Surgery and radiation treatment has been found to have modest effect on NSCL while chemotherapy is largely ineffective due to refractory nature of the cancerous cells. Tumor removal was one of the widely used treatments when effective therapeutics was not available to the patients. Over time, radiation therapy made its place but large number of side effects limited its widespread usage and it was replaced by radiofrequency ablation method which is used to destroy on spot lung tumor cells with the help of high frequency radio waves. Advent of chemotherapeutics medicines helped the patients undergoing surgery or radiation therapy upto limited extent. Targeted therapies came after chemotherapy and they made place in market due to higher safety and efficacy levels.

Targeted therapeutics seems to overtake the NSCLC market due to higher safety and efficacy profiles. Moreover, pharmaceutical companies are promoting them as a replacement for chemotherapeutics which used to dominate in NSCLC therapeutic market. In few cases, combinatorial therapies chemotherapeutics are used with targeted therapeutics but their market share is in decline and this trend is expected to be continued in future. Targeted therapeutics should not be considered as all-in-one treatment as they also have few limitations which are expected to be resolved in near future. The new generation of targeted therapeutics is expected to have refinement at the level of design which will be considered as evolved version of presently available targeted therapeutics.

Advances in monoclonal antibody (mAbs) development technology are expected to evolve further in coming years due to which they may become major NSCLC therapeutic in market. Their potency is expected to increase along with minimum side effects and increase in specificity. The marketing potential of mAbs is expected to increase as they have proven track record and widely accepted by oncologists and patients. The developers of mAbs would consider that the simultaneous evolution of targeted and enzyme inhibitor therapies coupled with other therapies are in developing stages which will give them severe competition after some time. Their market share may get eroded by new NSCLC therapeutics which is likely to provide better pharmacological effect at competitive pricing.

Large clinical development pipeline for NSCLC therapeutics is expected to grow at tremendous rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these therapeutics have prove their worth in clinical trials along with statistically significant data on safety and efficacy will be required. They will also take few years in passing regulatory hurdles and marketing authorization before providing medical care to NSCLC patients.

"Global Non Small Cell Lung Cancer Market & Pipeline Insight" Report Highlights:

  • NSCLC Therapy Market Overview
  • Mechanism of NSCLC Therapeutics
  • NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects)
  • NSCLC Drug Pipeline by Phase, Company & Country
  • NSCLC Clinical Pipeline: 268 Drugs
  • Majority of NSCLC Drugs in Phase-II Trials: 99
  • Marketed NSCLC Drugs: 30

Table of Contents

1. Introduction to Non Small Cell Lung Cancer

2. Mechanism of Non Small Cell Lung Cancer Therapeutics

3. Non Small Cell Lung Cancer Therapy Market Overview

  • 3.1 Market Scenario
  • 3.2 Non Small Cell Lung Cancer Pipeline Overview

4. Non Small Cell Lung Cancer Therapy Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Challenges

5. Non Small Cell Lung Cancer Therapy Market Future Prospects

6. Non Small Cell Lung Cancer Drug Pipeline by Phase, Company & Country

  • 6.1 Unknown
  • 6.2 Research
  • 6.3 Preclinical
  • 6.4 Clinical
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-II/III
  • 6.9 Phase-III
  • 6.10 Preregistration
  • 6.11 Registered

7. Marketed Non Small Cell Lung Cancer Drugs

8. Suspended & Discontinued Non Small Cell Lung Cancer Drug Pipeline

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Suspended

9. Competitive Landscape

  • 9.1 AstraZeneca
  • 9.2 Biodesix
  • 9.3 Chugai Pharmaceutical
  • 9.4 Eli Lily
  • 9.5 GlaxoSmithKline
  • 9.6 Merck
  • 9.7 Novartis AG
  • 9.8 Pfizer
  • 9.9 Roche
  • 9.10 Transgene
  • Figure 1-1: Classification of Lung Cancer
  • Figure 1-2: Treatments Available for NSCLC
  • Figure 1-3: Categorization of NSCLC on The Basis of Stages
  • Figure 2-1: Steps Involved in NSCLC Metastasis
  • Figure 2-2: Mechanism of Tyrosine Kinase Inhibitors
  • Figure 2-3: Mechanism of Angiogenesis Inhibitors
  • Figure 2-4: Mode of Action of NSCLC Vaccines
  • Figure 3-1: Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-2: Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
  • Figure 3-3: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-4: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
  • Figure 3-5: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-6: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-7: Suspended Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-8: Suspended Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
Back to Top